Aldaver

ApplicationT335, 336, 341 Truth hall, 193, Munji-ro, Yuseong-gu, Daejeon, Republic of Korea (KAIST, Munji Campus)Founded 2022· One of 690 Application companies tracked by AMPulse

A medical technology startup developing hyper-realistic, biopolymer-based artificial organ simulators designed for high-fidelity surgical training and medical device validation.

CEO / Founder: Kim Jin-oh, Steve Park
Team Size: 11-50
Stage: Active
Total Funding: $9.6M
Latest Round: Series A
Key Investors: SL Investment, Korea Investment Partners, Daily Partners, KB Investment, Ascendo Ventures, Bluepoint Partners

Technology & Products

Key Products

Biopolymer + 3D-printed artificial organ simulators for surgical training and device validation: BPH Treatment Simulator (Compact), TURBT, Kidney RIRS, Partial Nephrectomy, Prostatectomy, plus laparoscopy line expansion (2025). Online store at aldaver.co.kr/shop.

Technological Advantage

Leverages the founder's expertise in 'electronic skin' and flexible electronics to integrate sensory feedback into simulators, bridging the gap between static plastic models and living tissue.

Differentiation

Value Proposition

Provides a high-fidelity, ethical alternative to animal testing and human cadavers by mimicking the exact mechanical resistance and electrical conductivity of living human tissue.

How They Differentiate

Aldaver differentiates through its proprietary 'Liquid-to-Solid' biopolymer technology and 'electronic skin' expertise. Unlike traditional plastic models, Aldaver’s simulators mimic the exact electrical conductivity and mechanical resistance of living tissue, allowing for the realistic use of electrosurgical and robotic tools that typically fail on standard synthetic materials.

Market & Competition

Target Customers

Medical schools, teaching hospitals, surgical training centers, and global medical device manufacturers (R&D and sales divisions).

Industry Verticals

Medical Technology (MedTech), Healthcare Education, Surgical Robotics, Medical Device Manufacturing

Competitors

CAE Healthcare, IngMar Medical, SynDaver Labs

Growth & Milestones

Growth Metrics

Homepage metrics: 20 models, 160 partnering companies, 6,000 users; ~46–47 employees (THE VC / 국민연금 mid-2026); 4.4x valuation step-up Pre-A→Series A; dedicated manufacturing at Osong High-Tech Medical Complex; active global exhibition calendar through 2026.

Major Milestones

Recipient of the CES 2023 Innovation Award for realistic medical simulators, Successfully developed 'Liquid-to-Solid' biopolymer technology for haptic organ mimicry, Completed $8.4M Series A funding round in January 2025, Established specialized production line at Osong High-Tech Medical Complex

Notable Customers

Medical schools, teaching hospitals, surgical training centers, and global MedTech manufacturers (R&D/sales). Named activity with Teleflex (UroLift training); collaborations with VRiMS and Società Italiana di Andrologia (SIA); 160 partnering companies / 6,000 users claimed on site.

https://aldaver.co.kr

Why this company matters

AMPulse analysis, not a company disclosure

Aldaver produces hyper-realistic, biopolymer-based artificial organ simulators designed to replace animal testing and human cadavers in surgical training and medical device validation. Its proprietary 'Liquid-to-Solid' biopolymer technology creates synthetic tissues that replicate the haptic feedback and electrical conductivity of living human tissue, enabling realistic use of electrosurgical and robotic tools that fail on standard plastic models.

The company's simulators target urological and vascular procedures, skin, and benign prostatic hyperplasia (BPH). Customers include medical schools, teaching hospitals, surgical training centers, and global medical device manufacturers. Aldaver has collaborated with VRiMS and the Società Italiana di Andrologia (SIA), and works with Asan Medical Center for clinical validation.

Founded in 2021 and based at KAIST's Munji Campus in Daejeon, Aldaver leverages the founder's expertise in electronic skin and flexible electronics to integrate sensory feedback into its simulators. The company holds nine registered patents in the medical or veterinary science category. It raised an $8.4 million Series A in January 2025, bringing total funding to $9.6 million, with investors including SL Investment, Korea Investment Partners, and KB Investment.

Aldaver differentiates from competitors like CAE Healthcare, IngMar Medical, and SynDaver Labs through its focus on electrical conductivity and mechanical resistance matching. Its simulators allow electrosurgical tool testing that other synthetic materials cannot support. The company has established a dedicated manufacturing facility at the Osong High-Tech Medical Complex and received a CES 2023 Innovation Award.